2-[(1R,2R)-2-[(7-fluoro-2,3-dihydro-1H-inden-4-yl)oxy]cyclobutyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 2-[(1R,2R)-2-[(7-fluoro-2,3-dihydro-1H-inden-4-yl)oxy]cyclobutyl]-7-(4-methylimidazol-1-yl)-3,4-dihydropyrido[1,2-a]pyrazine-1,6-dione
• 化学式: C₂₅H₂₅FN₄O₃
• 分子量: 448.5
• InChiKey: KXUOSHAFWYNJPL-AUSIDOKSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  67.7
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Novel Bicyclic Pyridinones
  申请人：Pfizer Inc.

  公开号：US20140088111A1

  公开（公告）日：2014-03-27

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  所述化合物及其药用可接受盐已被披露，其中所述化合物具有规范中定义的Formula I结构。相应的药用组合物、治疗方法、合成方法和中间体也已被披露。
• Novel Pyrido[1,2-a]Pryazines And Their Use In The Treatment of Neurodegenerative and Neurological Disorders
  申请人：Pfizer Inc.

  公开号：US20150072990A1

  公开（公告）日：2015-03-12

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明揭示了化合物及其药学上可接受的盐，其中化合物的结构如规格中定义的公式I。同时还揭示了相应的药物组合物、治疗方法、合成方法和中间体。
• Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders
  申请人：Pfizer Inc.

  公开号：US20160024088A1

  公开（公告）日：2016-01-28

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本文披露了化合物及其药学上可接受的盐，其中该化合物的结构如规范中定义的I式。同时还披露了相应的药物组合物、治疗方法、合成方法和中间体。
• NOVEL BICYCLIC PYRIDINONES
  申请人：Pfizer Inc.

  公开号：EP2897956B1

  公开（公告）日：2016-11-09
• US8916564B2
  申请人：——

  公开号：US8916564B2

  公开（公告）日：2014-12-23